Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 12/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.74 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.74 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8110762 | 0.88 | HDAC2 (0.83) | HDAC2HDAC1HDAC3 | |
| SCHEMBL29741582 | 0.86 | HDAC1 (1.00) | HDAC2HDAC1HDAC3 | |
| SCHEMBL4655939 | 0.84 | HDAC2 (1.00) | HDAC2HDAC1HDAC3 | |
| SCHEMBL14155797 | 0.84 | HDAC2 (0.77) | HDAC2HDAC1HDAC3 | |
| SCHEMBL4579995 | 0.79 | HDAC1 (0.75) | HDAC2HDAC1HDAC3KCNH2 | |
| SCHEMBL16371520 | 0.78 | NPC1 (0.51) | HDAC2HDAC1HDAC3AAK1 | |
| SCHEMBL6995006 | 0.78 | NPC1 (0.51) | HDAC2HDAC1HDAC3 | |
| SCHEMBL13833373 | 0.77 | HDAC2 (0.77) | HDAC2HDAC1HDAC3AAK1 | |
| SCHEMBL13735514 | 0.77 | HDAC2 (0.74) | HDAC2HDAC1HDAC3 | |
| SCHEMBL4579545 | 0.77 | HDAC1 (0.73) | HDAC2HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194760-A1 | HETEROBICYCLIC N-AMINOPHENYL-AMIDES AS INHIBITORS OF HISTONE DEACETYLASE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
| EP-0056260-A1 | Pyridinyl-substituted-benz imidazole derivatives and preparation | STERLING DRUG INC. (US) | 1982-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194760-A1 | HETEROBICYCLIC N-AMINOPHENYL-AMIDES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC5 | HDAC2 1/4885HDAC1 2/4885HDAC3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.